Companion Diagnostic Tests Market in Oncology Benefited by Rising Cancer Patients

A new report by Transparency Market Research highlights recent developments in the companion diagnostic tests market in oncology. For many years, drug approval process remained costly, time-consuming, and complex; it still is. However, the adoption of companion diagnostic tests holds much promise to simplify the drug approval procedures. In recent years, companion diagnostic tests have gone through many advancements.

Download Exclusive Sample of this Report: http://bit.ly/2fzF9Tu

The application of personalized medicines and companion diagnostic tests is increasing in the oncology industry. These tests are being increasingly used in the oncology industry to find somatic mutations in the cells of a tumor. The rising application of these tests in non-small cell lung cancer is expected to propel the global companion diagnostic tests market in oncology. As per the findings of the report, currently, non-small cell lung cancer accounts for 50% of the global companion diagnostic tests market in oncology.

The report, titled “Companion Diagnostic Tests Market in Oncology - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” forecasts many changes in the global market, especially in the oncology area. According to the report, the advent of companion diagnostic tests will enhance patient outcomes evidently, minimize research and development expenditure, and also increase the approval rate of drugs. Although companion diagnostic tests will primarily transform the oncology area, it is also expected to have a positive impact on disease treatments. Advancements in companion diagnostic tests are predicted to increase many cost saving opportunities for companies operating in the global oncology market.

For a competitive analysis, the global companion diagnostic tests market is regionally divided into North America, Europe, the Middle East and Africa, Latin America, and Asia Pacific. The use of companion diagnostic tests is increasing in developing countries such as Brazil, China, and India. This is predicted to boost the global companion diagnostic tests market. The rise in the aging population and the increasing number of cancer patients are two of the primary factors expected to propel the global market in the years to come.

Some of the prominent players operating in the companion diagnostic tests market in oncology are Roche Diagnostics, Ventana Medical Systems, Inc., Beckman Coulter Inc., Genomic Health Inc., Leica Biosystems, Quest Diagnostics, Inc., Dako, Abbott Laboratories, Epigenomics AG, Qiagen, Celera, Labcorp, and Panacea Pharmaceuticals.

Browse Research Report: http://bit.ly/2f3x6dX

Key companies are focusing on introducing innovative personalized therapies for numerous treatment disorders. The rising government funding and focus towards the development of new companion diagnostic tests and favorable reimbursement policies are also expected to benefit the global market for companion diagnostic tests.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.